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SHORT COMMUNICATION
Comparison of the rapid automated MTT-assay with a dye exclusion
assay for chemosensitivity testing in childhood leukaemia
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Departments of IPediatrics and 2Oncology, Free University Hospital, de Boelelaan 1117, 1007 MB Amsterdam, The
Netherlands.
Many different assays have been developed to assess chemo-
sensitivity of malignant cells. The use of the clonogenic assay
has a number of theoretical (Weisenthal & Lippman, 1985)
but especially practical difficulties, such as a long incubation
time and low plating efficiencies resulting in adequate colony
forming in only 40% of all specimens (Carney & Winkler,
1985). Recently, Ajani et al. (1987) described a cell culture
system with a plating efficiency of 3%, allowing drug testing
in about 70% of tumours. Unfortunately, up to now such
plating efficiency is not obtained in specimens from patients
with acute lymphoblastic leukaemia (ALL). Even if one
succeeds in culturing ALL cells then a mean plating
efficiency of only 0.04% will be obtained (Touw et al., 1986).
Because of this, short-term tests might be more appropriate
for drug sensitivity testing of ALL cells. The most promising
short-term test is the dye exclusion assay (DEA) developed
by Weisenthal et al. (1983a). Others (Bosanquet et al., 1983;
Bird et al., 1986) have adapted this assay using the microtitre
format to study chemosensitivity of leukaemic patients. A
number of authors have shown that the end-point of the
DEA is comparable to that of the clonogenic assay
(Weisenthal et al., 1983b; Carmichael et al., 1987; Laurent et
al., 1986; Bird et al., 1987). With regard to the correlation
with clinical responsiveness, which is ultimately the most
valid comparison of different assays, the results of the DEA
compared favourable with those of other in vitro chemosensi-
tivity assays (Weisenthal & Lippman, 1985; Bird et al.,
1988). Therefore the DEA is a useful tool to study drug
sensitivity of ALL cells. However, this method is still very
labour-intensive and subject to observer error. These
problems can be overcome with the recently developed assay
based on the reduction of MTT (3-[4,5-dimethylthiazol-2-yl]-
2,5-diphenyl tetrazolium bromide) to a formazan by living
but not by dead cells (Mosmann, 1983). The MTT assay can
be performed in microtitre plates and the formazan
production can be quantitated with a microplate spectro-
photometer. Therefore it provides a simple, automated and
highly efficient method for chemosensitivity testing.
Up to now the MTT assay has been used to assess drug
sensitivity in established cell lines (Alley et al., 1988;
Carmichael et al., 1987; Cole, 1986; Finlay et al., 1986; Park
et al., 1987; Twentyman & Luscombe, 1987). If the MTT
assay would be applicable to leukaemia specimens and
would give results comparable to the DEA, it would greatly
facilitate monitoring of chemosensitivity. We recently
adapted the MTT assay for testing leukaemic samples
obtained directly from patients and optimised the test
conditions for this purpose (Pieters et al., 1988). The
comparison of the MTT assay with the DEA is described in
the present report.
myeloid blast cell crisis. Lymphoblasts were isolated and
washed as described before (Pieters et al., 1988). Specimens
were tested after thawing of cells that had been frozen in
liquid nitrogen. After cryopreservation the mean percentage
blast cells was 93% (range 80-98). In one patient a
comparison was made between the same specimen before
and after cryopreservation resulting in identical dose-
response curves (see Figure 1).
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Cells Bone marrow (BM) or blood was obtained from eight
children with initial ALL, one with a BM relapse of ALL
and one with chronic myeloid leukaemia (CML) at time of a
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Figure 1 Dose-response curves for the same specimen of a
single ALL patient before ( ) and after (------) cryo-
preservation. Abbreviations as in Table I.
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Test design The MTT assay and DEA were run
concurrently for each patient using 1 x 106 cellsml-l in
RPMI-FCS plus supplement as described before (Pieters et
al., 1988). Aliquots (80,ul) of this suspension were dispensed
into 96-well round-bottomed microtitre plates which already
contained 20M1 of drug dilutions. The 96-well plates were
incubated at 37°C for 2 days. Storage and dissolving of
drugs were done as previously described (Pieters et al., 1988).
MTT assay After 2 days incubation, 10,l1 MTT (Sigma)
solution (5mgml-1) was added to each well and after
shaking for 1min the plate was incubated further for 6h.
Formazan crystals were dissolved with 100pI of 0.04N HCl-
isopropyl alcohol. The absorbance or optical density (OD)
was quantitated with a microplate spectrophotometer
(Titertek Multiskan MCC 340) at 540nm. Wells containing
no cells and no drugs were used for blanking the spectro-
photometer. Leukaemic cell survival (LCS) for a well was
expressed as percentage of untreated control wells. The mean
coefficient of variation of OD of control wells (n=8 for each
patient) was 9.8%. We showed a linear relationship
(r2=0.998) between OD and cell number in the range of
80 x 103 cells (i.e. the number of cells seeded in a well) to
1.25 x 103 cells (Pieters et al., 1988).
Dye exclusion assay (DEA) The DEA was carried out using
a modification of the assay described by Weisenthal et al.
(1983a, b), Bird et al. (1986, 1988) and Bosanquet et al.
(1983). Following the 2 days incubation of the cells, 100pl
0.2% trypan blue containing 4x 104 duck red blood cells
(DRBC) as internal standard were added to each well. After
5min incubation at room temperature, aliquots from the
wells were cytocentrifuged at lOOg for 5min. The resultant
slides were air-dried, fixed with methanol and counterstained
with May-Grunwald-Giemsa (MGG). The ratio of living
(MGG stained) leukaemic cells over DRBC was determined
using a light microscope and counting at least 300 (in most
cases 500) DRBC per slide. The viable leukaemic cell/DRBC
ratio of a treated well was again expressed as percentage of
the untreated control wells and then called leukaemic cell
survival (LCS). In both assays LCS50 was defined as the
lowest concentration of a drug at which the LCS was <50.
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Figure 2 Dose-response curves for a single ALL patient.
Leukaemic cell survival (LCS), expressed as percentage of
controls, was assessed by the MTT assay ( -) and the dye
exclusion assay (-----). Abbreviations as in Table I.
Comparison In 3/10 samples the control cell viability in the
DEA was lower than 2% and the absolute OD value in the
control wells in the MTT assay was lower than 0.025. These
values were too low for reliable calculation of LCS. Both
assays were technically successful in 7/10 patients with a
mean control cell viability in the DEA of 39% (range 10-
59%) for ALL and 28% for myeloid cells. The mean
absolute OD values of the controls in the MTT assay were
0.121 (range 0.075-0.156) for ALL and 0.356 for myeloid
cells.
With respect to dose-response curves a good correlation
was observed between both assays as illustrated by the
examples in Figures 2 and 3. LCS50 values are shown in
Table I. In 26 cases (62%) the LCS50 was identical and in 38
cases (90%) the difference in LCS50 was _2 drug dilutions.
The main difference was the required processing time. The
MTT assay took only 15min of technician time after the 2
days incubation compared to 12-16h for the DEA.
Sometimes LCS values can exceed 100%. This has also
been observed in other studies (Park et al., 1987; Alley et al.,
1988). It is not clear which factor causes this effect. The
excess may fall within the coefficient of variation in some
cases. Higher values in the DEA might be due to observer
error, for example Dox in Figure 3. If the excess tends to
take place in all drugs then it is likely that the control value
has been assessed too low as in Figure 2. With respect to
Pred it is of interest that this drug stimulates in vitro
leukaemic cell growth in some cases (Salem et al., 1988).
Dose-response curves covering the LCS-range from 0 to
100% were found for 6-TG, 6-MP and VCR. In the case of
Dox and Pred the used doses might have been too low to
distinguish between sensitivity and resistance. In two ALL
patients in which Dox was not effective, a 4-day incubation
with a wider range of concentrations resulted in dose-
response curves at 1.6-25jg/ml. Using a 4-day incubation of
Pred in the five cases in which Pred was not effective, this
curve was demonstrable in two additional cases. The fact
that a number of ALL patients exhibit a poor response to
initial steroid therapy (Riehm et al., 1987) might also explain
the lack of in vitro effect of Pred in some cases. At present
we use a 4-day MTT assay with the highest doses of Pred
and Dox being 200pgml-1 and 8Mgml-1 respectively. A 4-
day incubation of MTX in four patients showed a cytotoxic
effect in all patients (LCS=35-70%).
It should be stressed that chemosensitivity assays are more
suitable for detecting the relative efficacy of drugs than the
absolute effect of a certain drug dose. In this respect it is of
interest to note that the ALL patient with a BM relapse was
less sensitive to VCR (LCS50= 50ngml-1) than initial ALL
patients (LC 50=0.8-3.lngml-1). This is in concordance
with the findings of Weisenthal et al. (1987). Using the DEA
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Figure 3 Dose-response curves for the CML patient at time of
a myeloblast cell crisis. Symbols as in Figure 2.
they showed that relapsed ALL patients were significantly
less sensitive to VCR than initial ALL patients and that the
relative resistance to VCR could be circumvented by protein
kinase C inhibitors. This has led to currently ongoing clinical
trials of these inhibitors, illustrating the fact that the DEA is
a useful tool to study chemosensitivity in ALL patients.
In testing chemosensitivity of cell lines, the MTT assay has
been shown to give results comparable to those obtained by
cellular protein assay (Alley et al., 1988), viable cell counting
Table I LCS50 values assessed by the MTT assay and dye
exclusion assay (DEA) for methotrexate (MTX), 6-thioguanine
(6-TG), 6-mercaptopurine (6-MP), prednisolone (Pred), vincristine
(VCR), and doxorubicin (Dox)
MTX 6-TG 6-MP Pred VCR Dox
Patient (y.gml-1) (ligml-') (ugml-U') (ngml-') (,gml-') (ngml-')
ALLI
MTT n.d. 25 62.5 >2,000 50 >500
DEA n.d. 25 125 >2,000 50 >500
ALL2
MTT >2,000 12.5 31.3 >2,000 6.3 >500
DEA 2,000 12.5 31.3 >2,000 1.6 >500
ALL3
MTT >2,000 50 >125 >2,000 3.1 500
DEA 1,000 50 62.5 >2,000 3.1 500
ALL4
MTT >2,000 >50 31.3 250 3.1 62.5
DEA >2,000 25 125 62.5 3.1 62.5
ALL5
MTT 250 3.1 7.8 >2,000 6.3 >500
DEA 500 1.6 7.8 >2,000 6.3 >500
ALL6
MTT >2,000 3.1 15.6 62.5 1.6 500
DEA >2,000 6.3 250 1,000 1.6 >250
CML7
MTT >2,000 3.1 7.8 >2,000 3.1 250
DEA >2,000 3.1 3.9 >2,000 3.1 250
(Finlay et al., 1986; Twentyman & Luscombe, 1987; Alley et
al., 1988) and clonogenic and dye exclusion assays
(Carmichael et al., 1987; Chang & Gregory, 1987; Harker et
al., 1987). However, with the exception of one paper in
Japanese (Hongo et al., 1987), there had been no data
available on the use of the MTT assay in drug sensitivity
testing of patient samples. After having this paper translated,
it appeared that the MTT assay often failed on initial ALL
samples because of the low control cell viability. In
accordance with the finding of Bird et al. (1986), we showed
that enrichment of the medium with insulin, transferrin and
selenite significantly increased the ALL cell viability which
allowed us to adapt the MTT assay for testing leukaemic
cells obtained directly from patients (Pieters et al., 1988). In
the present study we showed that the MTT assay and the
DEA correlated well for chemosensitivity testing in child-
hood leukaemia. In both assays the technical success rate
was 7/10, similar dose-response curves were observed in all
patients and a good correlation was observed for the LCS50
of both assays. However, the MTT assay is much more
efficient and rapid and not subject to observer error.
Conclusion The MTT assay and DEA give comparable
results in drug sensitivity testing of leukaemic blast cells of
children with leukaemia. Because of the fact that the MTT
assay is much more efficient and not subject to observer
error we conclude that the automated MTT assay offers the
more suitable method of assessing chemosensitivity in child-
hood leukaemia.
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